

1AP5 Rec'd PCT/PTO 21 MAR 2006

10/574087 Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Norikazu Ohtake, et al.

Int'l Appln.

No. : PCT/JP2004/013768

Int'l Date

Filed : 21 September 2004 (09/21/2004)

Serial No. : (To be assigned) Case No.: BY0031

Filed : March 21, 2006

For : NOVEL PIPERIDINE DERIVATIVE

Commissioner for Patents
Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

EXPRESS MAIL CERTIFICATE
DATE OF DEPOSIT 3-21-2006
EXPRESS MAIL NO. EV660608364 US
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS
BEING DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE"
ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO
COMMISSIONER FOR PATENTS, P.O. BOX 1450,
ALEXANDRIA, VIRGINIA 22313-1450,
MAILED BY Kathy Kluttsoule
DATE 3-22-06

Serial No.:
Case No.:
Page

To be assigned

BY 031
20/574087

IAP5 Rec'd PCT/PTO 21 MAR 2006

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

Pursuant to 37 CFR § 1.98(a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application are not enclosed herewith. Copies of the other references that are cited on the attached form PTO-1449 are enclosed herewith.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

By 
J. Eric Thies
Reg. No. 35,382
Attorney for Applicant

MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065-0907
(732) 594-3904

Date: March 21, 2006

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1 Attorney Docket Number BY0031

COMPLETE IF KNOWN

Application Number 10/574087	
Filing Date	March 21, 2006
First Named Inventor	Norikazu Ohtaku
Group Art Unit	
Examiner Name	

Sheet 1 of 1 Attorney Docket Number BY0031

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature _____ **Date Considered** _____
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of

Examiner: Initial in reference considered; whether or not citation is in conformance with MPEP 669. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.